2Tarxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials[J]. Med Res Rev,2001,21(6) :499-512.
3Rubin BP,Singer S,Tsao C,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors[J]. Cancer Res,2001, 61(22):8118-8121.
4Potti A, Moazzam N, Ramar K, et al. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma[J]. Ann Oncol,2003,14(6):894-897.
6Tamborini E,Papini D, Mezzelani A, et al. c-kit and c-kit ligand (SCF) in synovial sarcoma (SS) :an mRNA expression analysis in 23 cases[J]. Br J Cancer,2001,85(3) :405-411.
二级参考文献16
1Lewin KJ, Riddell RH, Weinstein WM, et al .Gastrointestinal pathology and its clinical implications. 1st ed. New York: Igaku-shoin. 1992,284-341.
2Nakahara M, Isozaki K, Hirota S, et al. A novel gain of function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology, 1998,115:1090-1095.
3Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987,6:3341-3351.
4Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res, 1999,59:4297-4300.
5Moskaluk CA, Tian Q, Marshall CR ,et al. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene, 1999,18:1897-1902.
6Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointesinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol, 1999,154:53-60.
8Salomo Rikala M, Kovatich AJ, Barusevcius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol, 1998,11:728-734.
9Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998,279:577-580.
10Ferlay J, Bray F, Pisani P, et al. GlOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide. Version 1.0.IARC CancerBase No 5[R]. Lyon, France: IARC press, 2001
